Amgen Inc. $AMGN Position Boosted by JB Capital LLC

JB Capital LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 361.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,941 shares of the medical research company’s stock after acquiring an additional 41,474 shares during the quarter. Amgen accounts for 0.7% of JB Capital LLC’s portfolio, making the stock its 26th largest position. JB Capital LLC’s holdings in Amgen were worth $17,328,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC raised its position in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares in the last quarter. Davis Capital Management bought a new position in shares of Amgen in the third quarter valued at approximately $1,841,000. D.A. Davidson & CO. increased its stake in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. increased its stake in shares of Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after acquiring an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in Amgen by 18.2% during the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $347.94 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $187.56 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s fifty day moving average is $363.65 and its 200-day moving average is $332.77.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Morgan Stanley upped their target price on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Daiwa Securities Group lifted their price target on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Royal Bank Of Canada boosted their price objective on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Jefferies Financial Group began coverage on Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.